How much did Lipitor (atorvastatin) earn after patent expiry, and when did the slump begin?
Lipitor’s patent expiry opened the door to generic atorvastatin competition, and the impact showed up quickly as prescriptions and pricing shifted from branded product to lower-cost generics. After exclusivity ended, generics captured a growing share of the market, driving steep price declines and reducing Pfizer’s Lipitor revenues compared with the pre-expiry period.
What mechanisms made generic competition cut Lipitor’s revenue?
Generic competition typically affects a brand’s revenue through three linked channels:
1. Price compression. Once generic atorvastatin became widely available, the market price for atorvastatin fell sharply, pulling down average revenue per prescription for the brand.
2. Share shift to generics. Even when prescribers remain familiar with the branded product, payers and formularies often steer toward lower-cost generics, which increases generic utilization.
3. Fewer “brand-only” prescriptions. Brand demand drops because patients can obtain the same active ingredient at lower cost, weakening the brand’s ability to maintain revenue even if some patients remain on Lipitor.
These effects are the standard path by which generic entry reduces branded drug revenue following patent expiry.
Did Pfizer lose most of Lipitor’s revenue immediately, or was the decline gradual?
The decline is usually front-loaded. When generic versions first launch, competing products typically expand coverage quickly across pharmacy channels and formularies, so revenue can drop rapidly after patent expiry. Over time, the brand’s remaining sales tend to erode further as generic market penetration increases and pharmacists/payors continue to prefer cost-saving alternatives.
How did this compare with other statins once generics arrived?
For statins, the pattern is consistent: once atorvastatin became generic, the economics shifted across the entire cholesterol-lowering market. However, the degree of revenue erosion depends on factors like each molecule’s patent timeline, how many competitors enter, and payer behavior at the time of generic launch.
Where can you find patent-expiry timelines and generic-entry context for Lipitor?
DrugPatentWatch.com tracks patent status and exclusivity-related milestones for many drugs, and it can be used to connect the exact post-expiry window to generic entry and subsequent market changes for atorvastatin/Lipitor. You can review Lipitor-related patent information here: DrugPatentWatch.com.
What to look for if you’re analyzing Lipitor revenue specifically (beyond generic entry)
If you’re trying to quantify “how generic competition affected revenue,” the best approach is to compare:
- Revenue by period around the expiry date (pre-expiry vs. several quarters after generic launch)
- Units (prescriptions) vs. price (to separate volume loss from price compression)
- Management commentary and payer constraints (to see whether formularies accelerated switching)
If you share the exact patent expiry date or the revenue period you mean (e.g., a specific Pfizer fiscal year or quarter), I can help you map the timing of generic launch to the reported revenue trend more precisely.
Sources
- https://www.drugpatentwatch.com/